Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Amyloid-β Peptide-specific DARPins as a Novel Class of Potential Therapeutics for Alzheimer Disease

13 Aug 2014

Abstract excerpt

Passive immunization with anti-amyloid-β peptide (Aβ) antibodies is effective in animal models of Alzheimer disease. With the advent of efficient in vitro selection technologies, the novel class of designed ankyrin repeat proteins (DARPins) presents an attractive alternative to the immunoglobulin scaffold. DARPins are small and highly stable proteins with a compact modular architecture ideal for high affinity...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Cholinesterase and Neurodegenerative Diseases
Share to Computational Drug Discovery Methods

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25118284
DOI: 10.1074/jbc.m114.564013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Amyloid-β Peptide-specific DARPins as a Novel Class of Potential Therapeutics for Alzheimer DiseasePMID 25118284Read ↗

Aptamers targeting amyloidogenic proteins and their emerging role in neurodegenerative diseasesSemantic proximity Read ↗

Design of non-aggregating variants of Aβ peptide.Semantic proximity Read ↗

Gene therapy using Aβ variants for amyloid reduction.Semantic proximity Read ↗

Designed Ankyrin Repeat Proteins (DARPins): Binding Proteins for Research, Diagnostics, and TherapySemantic proximity Read ↗

FDA-Approved Passive Immunization Treatments Against Aβ in Alzheimer’s Disease: Where Are We Now?Semantic proximity Read ↗

An in vitro paradigm to assess potential anti-Aβ antibodies for Alzheimer’s diseaseSemantic proximity Read ↗

Therapeutic Strategies Targeting Amyloid-β Receptors and Transporters in Alzheimer’s DiseaseSemantic proximity Read ↗

A novel bio-inspired strategy to prevent amyloidogenesis and synaptic damage in Alzheimer’s diseaseSemantic proximity Read ↗

Nanobody Therapeutics in Alzheimer’s Disease: From Molecular Mechanisms to Translational ApproachesSemantic proximity Read ↗

Strategies to gain novel Alzheimer’s disease diagnostics and therapeutics using modulators of ABCA transportersSemantic proximity Read ↗

Aggregation-Dependent Epitope Sequence and Modification Fingerprints of Anti-Aβ AntibodiesSemantic proximity Read ↗

Sequestration of the Aβ Peptide Prevents Toxicity and Promotes Degradation In VivoSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.